AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7855193 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol group AM (0.62 g/kg) with incentive for nonimpaired performance
Number of subjects: 24
Study 7855193 — intervention group
Group type: EXPERIMENTAL
Intervention: Group PM (incentive without KR)
Number of subjects: 24
Study 7855193 — intervention group
Group type: COMPARATOR
Intervention: Group PC (continued KR)
Number of subjects: 24
Study 3607147 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 grams of glucose
Number of subjects: 60
Study 3607147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28875242 — intervention group
Group type: EXPERIMENTAL
Intervention: Needs-based education
Number of subjects: 450
Study 28875242 — intervention group
Group type: COMPARATOR
Intervention: Traditional education
Number of subjects: 450
Study 27965882 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Personalised Care After Treatment for Gynaecological cancer (OPCAT-G) intervention
Number of subjects: 0
Study 27965882 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 25211663 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2/neu positive cases
Number of subjects: 1645
Study 25211663 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2/neu positivity
Number of subjects: 1645
Study 25211663 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2/neu positive status in sigmoideal and rectal carcinomas
Number of subjects: 1645
Study 25211663 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2/neu positive colorectal carcinomas
Number of subjects: 1645
Study 21807750 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of guided self-help intervention targeting abstract rumination
Number of subjects: 34
Study 21807750 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition receiving treatment as usual
Number of subjects: 34
Study 20588170 — intervention group
Group type: EXPERIMENTAL
Intervention: Latest CD4(+) cell count
Number of subjects: 3012
Study 20588170 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4(+) slope < -10 cells/microl per month
Number of subjects: 3012
Study 20588170 — intervention group
Group type: COMPARATOR
Intervention: Non-AIDS deaths
Number of subjects: 3012
Study 20588170 — intervention group
Group type: COMPARATOR
Intervention: Non-AIDS events
Number of subjects: 3012
Study 19001323 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation docetaxel 75 mg/m2 IV every 21 days for three cycles
Number of subjects: 203
Study 19001323 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 203
Study 19001323 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival comparison
Number of subjects: 203
Study 19001323 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicities during docetaxel
Number of subjects: 203
Study 16430387 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring using the @HOME platform
Number of subjects: 108
Study 16430387 — intervention group
Group type: COMPARATOR
Intervention: Self-report
Number of subjects: 108
Study 16430387 — intervention group
Group type: COMPARATOR
Intervention: Pill counting
Number of subjects: 108
Study 12791563 — intervention group
Group type: EXPERIMENTAL
Intervention: Early attachment-oriented preventive psychotherapeutic intervention program
Number of subjects: 87
Study 12791563 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 87
Study 12791563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 87
Study 10321786 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 51
Study 10321786 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 51
Study 7493593 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic priming task for older adults
Number of subjects: 0
Study 7493593 — intervention group
Group type: COMPARATOR
Intervention: Semantic priming task for young adults
Number of subjects: 0
Study 7493593 — intervention group
Group type: EXPERIMENTAL
Intervention: Inconsistent responding older individuals
Number of subjects: 0
Study 1673478 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (30 mcg.kg‐1)
Number of subjects: 21
Study 1673478 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (50 mcg.kg‐1)
Number of subjects: 21
Study 1673478 — intervention group
Group type: COMPARATOR
Intervention: Control (no Ca entry blocker)
Number of subjects: 21
Study 6956947 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (enteral route)
Number of subjects: 26
Study 6956947 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 26
Study 31701799 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone with spironolactone (R + S)
Number of subjects: 138
Study 31701799 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone with metformin (R + M)
Number of subjects: 138
Study 31701799 — intervention group
Group type: COMPARATOR
Intervention: rosiglitazone (R)
Number of subjects: 138
Study 31073102 — intervention group
Group type: EXPERIMENTAL
Intervention: NC120
Number of subjects: 49
Study 31073102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 27994065 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy
Number of subjects: 85
Study 25744509 — intervention group
Group type: EXPERIMENTAL
Intervention: High amylose maize resistant starch (RS) incorporated into fried wheat flour dough, given twice daily for 28 days.
Number of subjects: 17
Study 24885993 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% transfluthrin coils alone
Number of subjects: 7341
Study 24885993 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltamethrin long-lasting insecticide treated nets (LLINs) alone
Number of subjects: 7341
Study 24885993 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of transfluthrin coils and deltamethrin LLINs
Number of subjects: 7341
Study 24885993 — intervention group
Group type: COMPARATOR
Intervention: Control arm (nothing)
Number of subjects: 7341
Study 22859243 — intervention group
Group type: EXPERIMENTAL
Intervention: NB-001 (0.3%)
Number of subjects: 482
Study 19629023 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (PAROX)
Number of subjects: 52
Study 19629023 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoamine oxidase inhibitors (MAOIs)
Number of subjects: 52
Study 17317358 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS stent
Number of subjects: 155
Study 17317358 — intervention group
Group type: COMPARATOR
Intervention: bare metal stent
Number of subjects: 155
Study 15169848 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ascorbic acid (500 mg day(‐1)) and RRR‐alpha‐tocopherol (400 i.u. day(‐1))
Number of subjects: 14
Study 15169848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11489683 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide (150 mg daily)
Number of subjects: 3603
Study 11489683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3603
Study 9564984 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine with erythromycin
Number of subjects: 80
Study 9564984 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 80
Study 9564984 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 80
Study 9564984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 80
Study 9564984 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine without erythromycin
Number of subjects: 80
Study 9564984 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole without erythromycin
Number of subjects: 80
Study 9564984 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine without erythromycin
Number of subjects: 80
Study 9564984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine without erythromycin
Number of subjects: 80
Study 7981579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 0.014 mg/kg body weight
Number of subjects: 48
Study 7981579 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 0.028 mg/kg body weight
Number of subjects: 48
Study 7981579 — intervention group
Group type: COMPARATOR
Intervention: Control (0 mg/kg body weight)
Number of subjects: 48
Study 3236585 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued recall test
Number of subjects: 54
Study 3236585 — intervention group
Group type: COMPARATOR
Intervention: Recognition test
Number of subjects: 54
Study 3236585 — intervention group
Group type: EXPERIMENTAL
Intervention: Successive testing (recognition followed by recall)
Number of subjects: 54
Study 3236585 — intervention group
Group type: COMPARATOR
Intervention: Reverse order testing (recall followed by recognition)
Number of subjects: 54
Study 4666629 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic prostaglandin F2α and intravenous oxytocin
Number of subjects: 57
Study 4666629 — intervention group
Group type: COMPARATOR
Intervention: Intra-amniotic prostaglandin F2α alone
Number of subjects: 57
Study 4666629 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic prostaglandin F2α with oxytocin
Number of subjects: 57
Study 29428199 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 concentration in AF patients
Number of subjects: 254
Study 29428199 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 concentration in emergency AF patients
Number of subjects: 254
Study 29428199 — intervention group
Group type: COMPARATOR
Intervention: sST2 concentration in AF outpatients
Number of subjects: 254
Study 29428199 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 concentration in paroxysmal AF patients
Number of subjects: 254
Study 29428199 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 concentration in persistent AF patients
Number of subjects: 254
Study 29428199 — intervention group
Group type: COMPARATOR
Intervention: sST2 concentration in healthy individuals
Number of subjects: 254
Study 29428199 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 concentration as a predictor
Number of subjects: 254
Study 27429113 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined alfacalcidiol and metformin therapy (Group 2)
Number of subjects: 39
Study 27429113 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (Group 3)
Number of subjects: 39
Study 27429113 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidiol (Group 1)
Number of subjects: 39
Study 27429113 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 39
Study 24939928 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3202
Study 24939928 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus glycoprotein IIb/IIIa inhibitor
Number of subjects: 3202
Study 24939928 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 3202
Study 24939928 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents
Number of subjects: 3202
Study 24939928 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinfarction
Number of subjects: 3202
Study 22835552 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile flow during CPB
Number of subjects: 20
Study 22835552 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile flow during CPB
Number of subjects: 20
Study 20420643 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily calcineurin inhibitor (CNI) monotherapy at half their previous dose
Number of subjects: 56
Study 20420643 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily calcineurin inhibitor (CNI) monotherapy
Number of subjects: 56
Study 18684276 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic cardiography (EMAT)
Number of subjects: 43
Study 18684276 — intervention group
Group type: COMPARATOR
Intervention: Doppler echocardiography (transmitral flow assessment)
Number of subjects: 43
Study 18684276 — intervention group
Group type: COMPARATOR
Intervention: Doppler echocardiography (VTI)
Number of subjects: 43
Study 16882425 — intervention group
Group type: EXPERIMENTAL
Intervention: Lap Loop device
Number of subjects: 29
Study 16882425 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods (laparoscopic monopolar scissors or Harmonic scalpel)
Number of subjects: 29
Study 12523915 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment
Number of subjects: 331
Study 12523915 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients not using CPAP)
Number of subjects: 331
Study 10849243 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 8
Study 10849243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10849243 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem and Placebo
Number of subjects: 8
Study 8538349 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 81
Study 8538349 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 81
Study 8538349 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 81
Study 1651738 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ANP infusion (0.005 microgram/kg/min for 1 h)
Number of subjects: 12
Study 1651738 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ANP infusion (0.05 microgram/kg/min for 1 h)
Number of subjects: 12
Study 1651738 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline levels)
Number of subjects: 12
Study 6341102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 2 mg daily per os
Number of subjects: 10
Study 6341102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6341102 — intervention group
Group type: COMPARATOR
Intervention: Oral disodium cromoglycate
Number of subjects: 10
Study 6341102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 10
Study 31210177 — intervention group
Group type: EXPERIMENTAL
Intervention: Tavipec® (Spicae aetheroleum) 150 mg, 2 capsules thrice daily for 7 days
Number of subjects: 288
Study 31210177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 29694963 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil treatment
Number of subjects: 0
Study 26758999 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration during percutaneous coronary intervention (PCI)
Number of subjects: 7244
Study 26758999 — intervention group
Group type: COMPARATOR
Intervention: PCI-only
Number of subjects: 7244
Study 26758999 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration during PCI
Number of subjects: 7244
Study 24483158 — intervention group
Group type: EXPERIMENTAL
Intervention: PDRN
Number of subjects: 216
Study 24483158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 23030673 — intervention group
Group type: EXPERIMENTAL
Intervention: Water ingestion (50 mL)
Number of subjects: 19
Study 23030673 — intervention group
Group type: EXPERIMENTAL
Intervention: Water ingestion (500 mL)
Number of subjects: 19
Study 23030673 — intervention group
Group type: COMPARATOR
Intervention: Control (no water ingestion)
Number of subjects: 19
Study 20306530 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression bandaging for 24 hours
Number of subjects: 124
Study 20306530 — intervention group
Group type: COMPARATOR
Intervention: Compression bandaging for 5 days
Number of subjects: 124
Study 17147487 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of physical activity (PA)
Number of subjects: 1008
Study 17147487 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake (CI) in excess of 1039 mg/day
Number of subjects: 1008
Study 17147487 — intervention group
Group type: COMPARATOR
Intervention: High levels of physical activity (PA) and low calcium intake (CI)
Number of subjects: 1008
Study 16311449 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive measurement of intracranial blood volume (IBV) pulse waveforms
Number of subjects: 75
Study 16311449 — intervention group
Group type: COMPARATOR
Intervention: Control group of healthy volunteers
Number of subjects: 75
Study 11927731 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV vaccine coadministered with Hib vaccines (groups 1-4)
Number of subjects: 5318
Study 11927731 — intervention group
Group type: COMPARATOR
Intervention: Commercially available control vaccines (DTPa, Hib, and OPV) administered separately (group 5)
Number of subjects: 5318
Study 11927731 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa-HBV-IPV vaccine
Number of subjects: 5318
Study 11927731 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib N meningitidis outer-membrane complex protein conjugate vaccine
Number of subjects: 5318
Study 10216145 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy (9 million units three times a week for 38 +/- 8 weeks or 49 +/- 13 weeks)
Number of subjects: 157
Study 10216145 — intervention group
Group type: COMPARATOR
Intervention: Interferon therapy (44.8 +/- 27.4 weeks)
Number of subjects: 157
Study 10216145 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon therapy
Number of subjects: 157
Study 8785887 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical treatment with calcipotriene
Number of subjects: 0
Study 2131925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150mg bd
Number of subjects: 75
Study 2131925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300mg bd
Number of subjects: 75
Study 2131925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150mg at bedtime (maintenance)
Number of subjects: 75
Study 2131925 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300mg at bedtime (maintenance)
Number of subjects: 75
Study 92202 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct argon laser photocoagulation to the fluorescein leaking site
Number of subjects: 2
Study 92202 — intervention group
Group type: COMPARATOR
Intervention: Indirect treatment away from the leak
Number of subjects: 2
Study 31925579 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil
Number of subjects: 240
Study 31925579 — intervention group
Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 240
Study 31540168 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary weight loss and lifestyle intervention combined with usual care
Number of subjects: 84
Study 31540168 — intervention group
Group type: COMPARATOR
Intervention: Usual care (i.e., continuous positive airway pressure)
Number of subjects: 84
Study 28731642 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of diet quality (total food score > 36)
Number of subjects: 146
Study 28731642 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of diet quality (total food score < 36)
Number of subjects: 146
Study 28731642 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartiles of diet quality
Number of subjects: 146
Study 25346345 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment Group (PRTG)
Number of subjects: 53
Study 25346345 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation Group (PEG)
Number of subjects: 53
Study 24163593 — intervention group
Group type: EXPERIMENTAL
Intervention: Student peer assessment (SPA) training, practice with assessment rubrics, and application of anonymous SPA to assignments.
Number of subjects: 71
Study 24163593 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SPA training).
Number of subjects: 71
Study 21719638 — intervention group
Group type: EXPERIMENTAL
Intervention: COPCA
Number of subjects: 46
Study 21719638 — intervention group
Group type: COMPARATOR
Intervention: TIP
Number of subjects: 46
Study 20020572 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasofoxifene 0.5 mg
Number of subjects: 8556
Study 20020572 — intervention group
Group type: COMPARATOR
Intervention: Lasofoxifene
Number of subjects: 8556
Study 20020572 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 8556
Study 16938689 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational group intervention
Number of subjects: 128
Study 16938689 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 128
Study 15231008 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 (500 IU/day) and calcium (500 mg/day) during winter months (October-April)
Number of subjects: 55
Study 15231008 — intervention group
Group type: COMPARATOR
Intervention: No supplements (control group)
Number of subjects: 55
Study 11420592 — intervention group
Group type: EXPERIMENTAL
Intervention: Suctioning techniques (including preoxygenation, hyperinflation, insufflation, hyperoxygenation, hyperventilation, saline instillation, adaptor use, medication use, open and closed systems, and various types of catheters)
Number of subjects: 0
Study 9243440 — intervention group
Group type: EXPERIMENTAL
Intervention: Recorded delivery reminders
Number of subjects: 0
Study 9243440 — intervention group
Group type: COMPARATOR
Intervention: Telephone reminders
Number of subjects: 0
Study 8420303 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil
Number of subjects: 14
Study 8420303 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 2870956 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 0.25 +/- 0.25 mg iv
Number of subjects: 9
Study 2870956 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol 1 mg iv
Number of subjects: 9
Study 2870956 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 15 mg iv (pretreatment)
Number of subjects: 9
Study 2870956 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 10 mg iv (pretreatment)
Number of subjects: 9
Study 2870956 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol infusion
Number of subjects: 9
Study 30074128 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 3.75 mg/day
Number of subjects: 129
Study 30074128 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 2.5 mg/day
Number of subjects: 129
Study 30074128 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/day
Number of subjects: 129
Study 26922192 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-Assisted Telehealth Parent-Mediated Intervention
Number of subjects: 0
Study 26922192 — intervention group
Group type: COMPARATOR
Intervention: Self-Directed Telehealth Parent-Mediated Intervention
Number of subjects: 0